How do you decide on a salvage regimen for relapsed/refractory DLBCL, assuming a patient is transplant eligible?

Community
Company
News
Contact Us
Sign in

There are multiple options that carry a category 2B recommendation in the NCCN guidelines. Does germinal B center type vs activated B-cell type play a role?

Related Questions

What is the optimal choice of therapy for a patient with Hodgkin variant of Richter's transformation from underlying CLL/SLL?

What is your preferred third-line therapy for a fit patient with symptomatic, relapsed follicular lymphoma who has failed bendamustine-rituximab and lenalidomide-rituximab?

How would you treat cold agglutinin disease secondary to underlying marginal zone lymphoma with only bone marrow involvement and no disease elsewhere?

When would you consider treating an asymptomatic patient with follicular lymphoma?

What is your standard approach to treatment of plasmablastic lymphoma in HIV negative patients?

Following the BRUIN data in mantle cell lymphoma, will you routinely treat with pirtobrutinib following a covalent BTKi?

How would you treat an otherwise healthy patient with newly diagnosed Stage IIA unfavorable classical Hodgkin lymphoma who has exceeded lifetime anthracycline dose (for other indications, not treated previously for Hodgkins)?

Will you recommend pirtobrutinib following a prior covalent BTKi in patients with cardiac comorbidities?

How would you manage a pre-menopausal woman with extranodal marginal zone lymphoma confined to the bladder wall?

Are there biomarkers or other factors to help predict which patients with MCL are most likely to benefit, or not, from pirtobrutinib following a prior covalent BTKi?